Anaplastic Large Cell Lymphoma (ALCL)
Overview
Anaplastic Large Cell Lymphoma is a Mature T and NK Neoplasm (parent MTNN) and includes ALK-positive and ALK-negative subtypes.
Cohorts in the corpus
- mtnn_msk_2022: ALK− ALCL comprised 11% and ALK+ ALCL 5% of the 132-patient nodal PTCL cohort PMID:37078708.
Recurrent alterations
- TP53 mutations and 17p deletions were the only somatic aberrancies independently correlated with inferior PFS on CHOP-based chemotherapy in the broader PTCL cohort PMID:37078708.
- CDKN2A deletions correlated with markedly inferior OS in the PTCL cohort PMID:37078708.
- PIPseq cohort included anaplastic large cell lymphoma (ALCL) cases; DICER1 D609Y variant of uncertain significance returned as a VOUS to the patient’s family PMID:28007021
Subtypes
- ALCLALKP (ALK-positive) — 5% of the cohort PMID:37078708.
- ALCLALKN (ALK-negative) — 11% of the cohort PMID:37078708.
Therapeutic landscape
- Curative-intent CHOP-based chemotherapy, with brentuximab-vedotin-containing regimens (BV-CH(E)P) representing 12% of regimens used PMID:37078708.
Sources
This page was processed by crosslinker on 2026-04-10. - PMID:28007021
This page was processed by wiki-cli on 2026-05-14.